Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Chiara Macchi
Total Records ( 2 ) for Chiara Macchi
  Elisa Giuliani and Chiara Macchi
  Developing countries are attracting a significant portion of global foreign direct investments. Governments of such countries often compete fiercely for attracting multinational corporations (MNCs) in the expectation of the advantages they will bring to their economies, often prioritising economic goals over fundamental human rights. For a long time, economists have analysed the economic impacts of MNCs, while a parallel strand of work in political science, business ethics and international law investigates the repercussions of MNC operations on human rights. Despite the significant relatedness and complementarities, these two bodies of literature have so far poorly interacted. This paper addresses this limitation and systematically analyses and integrates existing micro-level empirical evidence on the economic and human rights impacts of MNCs on developing countries. It provides a critical analysis of what is known and highlights what we do not know about the factors that mediate the positive and/or negative impacts of MNC operations on host developing countries. Based on a critical analysis of the literature, it discusses avenues for future research in this field and sets the grounds for a new interdisciplinary research agenda on this subject.
  Massimiliano Ruscica , Monica Gomaraschi , Giuliana Mombelli , Chiara Macchi , Raffaella Bosisio , Franco Pazzucconi , Chiara Pavanello , Laura Calabresi , Anna Arnoldi , Cesare R. Sirtori and Paolo Magni


Primary cardiovascular prevention may be achieved by lifestyle/nutrition improvements and specific drugs, although a relevant role is now emerging for specific functional foods and nutraceuticals.


The aim of this study was to evaluate the usefulness of a nutraceutical multitarget approach in subjects with moderate cardiovascular risk and to compare it with pravastatin treatment.


Thirty patients with moderate dyslipidemia and metabolic syndrome (according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults) were included in an 8-week randomized, double-blind crossover study and took either placebo or a nutraceutical combination that contained red yeast rice extract, berberine, policosanol, astaxanthin, coenzyme Q10, and folic acid (Armolipid Plus). Subsequently, they were subjected to another 8-week treatment with pravastatin 10 mg/d. This dosage was selected on the basis of its expected −20% efficacy in reducing low-density lipoprotein-cholesterol.


Treatment with Armolipid Plus led to a significant reduction of total cholesterol (−12.8%) and low-density lipoprotein-cholesterol (−21.1%), similar to pravastatin (−16% and −22.6%, respectively), and an increase of high-density lipoprotein-cholesterol (4.8%). Armolipid Plus improved the leptin-to-adiponectin ratio, whereas adiponectin levels were unchanged.


These results indicate that this nutraceutical approach shows a lipid-lowering activity comparable to pravastatin treatment. Hence, it may be a safe and useful option, especially in conditions of moderate cardiovascular risk, in which a pharmacologic intervention may not be appropriate.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility